Doxil and Aldactone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Doxil (doxorubicin hydrochloride) and Aldactone (spironolactone). Common drug interactions include diarrhoea among females and dyspnoea among males.

The phase IV clinical study analyzes what interactions people have when they take Doxil and Aldactone. It is created by eHealthMe based on reports of 51 people who take the same drugs from the FDA, and is updated regularly.

What is Doxil?

Doxil has active ingredients of doxorubicin hydrochloride. It is often used in ovarian cancer. eHealthMe is studying from 10,479 Doxil users. Check the latest studies of Doxil.

What is Aldactone?

Aldactone has active ingredients of spironolactone. It is often used in acne. eHealthMe is studying from 46,063 Aldactone users. Check the latest studies of Aldactone.



On Jul, 29, 2026

51 people who take Doxil and Aldactone together, and have interactions are studied.

Doxil and Aldactone drug interactions.

What are the common drug interactions of Doxil and Aldactone, by gender? *:

female:

  1. Diarrhoea
  2. Dilated cardiomyopathy
  3. Drug hypersensitivity
  4. Dyspnoea (difficult or laboured respiration)
  5. Fall
  6. Food intolerance (inability to have food)
  7. Glomerular filtration rate decreased
  8. Hepatomegaly (abnormal enlargement of the liver)
  9. Hyperbilirubinaemia (excess of bilirubin in the blood)
  10. Hypophagia (reduced food intake)

male:

  1. Dyspnoea (difficult or laboured respiration)
  2. Haematocrit decreased
  3. Bacterial infection
  4. Blood urine present
  5. Cough
  6. Excoriation (to tear or wear off the skin of)
  7. Fracture
  8. General nutrition disorder
  9. Glossitis (infection of tongue with soreness)
  10. Hepatic failure (liver failure)

What are the common drug interactions of Doxil and Aldactone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Bacterial infection
  2. General nutrition disorder
  3. Haematocrit decreased
  4. Neutrophil percentage increased
  5. Platelet count decreased
  6. Pleural effusion (water on the lungs)
  7. Pneumonia

30-39:

n/a

40-49:

  1. Refractory anaemia with an excess of blasts (one or more cell types are low in the blood and look abnormal in the bone marrow)
  2. Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
  3. Enterococcal infection
  4. Stenotrophomonas infection
  5. Sinusitis (inflammation of sinus)
  6. Gingival ulceration (ulcer on gums)
  7. Bacterial sepsis
  8. Ascites (accumulation of fluid in the abdominal cavity)
  9. Asthma
  10. Fatigue (feeling of tiredness)

50-59:

  1. Arthralgia (joint pain)
  2. Glomerular filtration rate decreased
  3. Malignant neoplasm progression (cancer tumour came back)
  4. Myalgia (muscle pain)
  5. Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)

60+:

  1. Cancer pain
  2. Malignant ascites (a condition in which a person with cancer has an accumulation of fluid in the abdomen)
  3. Anaemia (lack of blood)
  4. Bacteraemia (presence of bacteria in the blood)
  5. Fatigue (feeling of tiredness)
  6. Alopecia (absence of hair from areas of the body)
  7. Compression fracture (fracture due to pressure caused by injury)
  8. Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)
  9. Depression
  10. Haematocrit decreased

What are the existing conditions these people have? *

  1. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 13 people, 25.49%
  2. Diffuse Large B-Cell Lymphoma Stage Iv (cancer of b cells, a type of white blood cell-stage iv): 13 people, 25.49%
  3. Refractory Anaemia With An Excess Of Blasts (one or more cell types are low in the blood and look abnormal in the bone marrow): 12 people, 23.53%
  4. High Blood Pressure: 8 people, 15.69%
  5. Ovarian Cancer Recurrent (reoccurrence of ovary cancer): 6 people, 11.76%
  6. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 6 people, 11.76%
  7. Ovarian Cancer (cancer of ovary): 6 people, 11.76%
  8. Multiple Myeloma (cancer of the plasma cells): 5 people, 9.80%
  9. Malignant Ascites (a condition in which a person with cancer has an accumulation of fluid in the abdomen): 5 people, 9.80%
  10. Leukopenia (less number of white blood cells in blood): 5 people, 9.80%

* Approximation only. Some reports may have incomplete information.

Do you take Doxil and Aldactone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Doxil and Aldactone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Doxil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Aldactone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Doxil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Aldactone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on doxorubicin hydrochloride and spironolactone (the active ingredients of Doxil and Aldactone, respectively), and Doxil and Aldactone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: